Pfizer divests Chinese animal vaccines to settle antitrust concerns
This article was originally published in Scrip
Executive Summary
Pfizer has completed the divestment of part of its animal health operations in China to a state-owned group in order to satisfy a local antitrust ruling following its global merger with Wyeth.